Summit Therapeutics Inc. (BMV:SMMT)
Mexico · Delayed Price · Currency is MXN | Market Cap | 236.16B -27.8% |
| Revenue (ttm) | n/a |
| Net Income | -21.74B |
| EPS | -28.72 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,500 |
| Open | 290.12 |
| Previous Close | n/a |
| Day's Range | 290.12 - 290.12 |
| 52-Week Range | 281.00 - 430.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 4, 2026 |
About Summit Therapeutics
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth facto... [Read more]
News
An experimental lung-cancer drug could replace Keytruda one day. But investors aren't wowed.
The highly anticipated study found that ivonescimab reduced the risk of death by 34% compared with another drug
Summit Therapeutics Transcript: Status update
Ivonescimab plus chemotherapy demonstrated a significant overall survival benefit in advanced squamous NSCLC, with consistent efficacy across PD-L1 subgroups and a favorable safety profile. Positive phase II CRC data and ongoing global phase III trials support its potential as a new standard of care in multiple solid tumors.
Summit Therapeutics Press release: Status update
Summit Therapeutics issued a press release on June 1, 2026, disclosing material business information to investors.
Summit Therapeutics Slides: Status update
Summit Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 1, 2026.
Summit rises after lung cancer drug trial shows 15% higher survival rate than rival's
Summit Therapeutics' shares rose as much as 7% before the bell after its ivonescimab therapy with China-based partner Akeso helped advanced lung cancer patients live 15% longer than BeOne Medicines' ...
Summit Therapeutics announces OS results from Phase 3 HARMONi-6 trial
Summit Therapeutics (SMMT) announced overall survival, OS, results from the Phase III HARMONi-6 trial, conducted in China and sponsored by Summit’s partner Akeso, will be presented as part of the…
Summit Therapeutics presents new results from AK112-206 trial
Summit Therapeutics (SMMT) presented new results from the AK112-206 trial, a global, open-label, multicenter Phase II study in first-line metastatic colorectal cancer co-sponsored by Summit and Akeso,...
Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced positive overall survival (OS) results from the Phase III HARMONi-6 trial, conducted in China and sponsored by...
A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China
An experimental lung cancer drug from Akeso and Summit Therapeutics improved survival in the Harmoni-6 Phase 3 trial conducted in China, according to results being presented at the American Society of...
Encouraging Global Phase II Ivonescimab Data in First-Line Metastatic Colorectal Cancer Presented at ASCO 2026
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today presented new results from the AK112-206 trial (NCT05382442), a global, open-label, multicenter Phase II study in first-...
Summit Therapeutics management to meet with Cantor
Breakfast Meeting with Management to be held in Chicago on June 2 hosted by Cantor.
Summit Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright downgraded Summit Therapeutics (SMMT) to Neutral from Buy without a price target The firm is concerned by the continued absence of a more mature HARMONi-2 OS update. Without…
Bernstein starts Summit with an Underperform, says ‘not on solid footing’
Bernstein analyst Jeffrey Walch initiated coverage of Summit Therapeutics (SMMT) with an Underperform rating and $7.70 price target The firm recommended investors “exit positions or, if possible, init...
Summit Therapeutics initiated with an Underperform at Bernstein
Bernstein initiated coverage of Summit Therapeutics (SMMT) with an Underperform rating and $7.70 price target
3 Best Stocks to Buy This Week, According to Analysts – May 18-May 22
Three names are expected to have strong setups this week: Zeta Global ($ZETA), Boston Scientific ($BSX), and Summit Therapeutics ($SMMT). Each stock has its own catalyst, and analysts see room…
Summit Therapeutics Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Summit Therapeutics Inc. (NASDAQ: SMMT). The investigation focuses on Summi...
Summit Therapeutics price target lowered to $23 from $30 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Summit Therapeutics (SMMT) to $23 from $30 and keeps a Buy rating on the shares. The firm says the absence of a…
Summit Therapeutics falls -23.7%
Summit Therapeutics (SMMT) is down -23.7%, or -$5.08 to $16.38.
Summit Therapeutics falls -27.4%
Summit Therapeutics (SMMT) is down -27.4%, or -$5.88 to $15.58.
Summit Therapeutics price target lowered to $16 from $17 at Piper Sandler
Piper Sandler lowered the firm’s price target on Summit Therapeutics (SMMT) to $16 from $17 and keeps a Neutral rating on the shares. The firm notes the company reported Q1…
Summit Therapeutics price target lowered to $31 from $32 at Clear Street
Clear Street lowered the firm’s price target on Summit Therapeutics (SMMT) to $31 from $32 and keeps a Buy rating on the shares. An interim PFS analysis was performed on…
Summit Therapeutics reports Q1 adjusted EPS (15c), consensus (21c)
Operational progress continues with ivonescimab (SMT112), an investigational, potentially first-in-class bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti...
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2026
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on clinical and operational prog...
Summit Therapeutics Earnings release: Q1 2026
Summit Therapeutics released its Q1 2026 earnings on April 30, 2026, summarizing the period's financial results.
Summit Therapeutics Quarterly report: Q1 2026
Summit Therapeutics has published its Q1 2026 quarterly earnings report on April 30, 2026.